Low level laser therapy in primary Raynaud's phenomenon--results of a placebo controlled, double blind intervention study.

What the authors concluded

Intensity of attacks was only slightly reduced during placebo phase (about 96% of pretreatment intensity), while laser therapy resulted in a highly significant reduction to about 82%, with a decreasing trend during the 3-week therapy period. Although all thermographic measures compared favorably for laser therapy, none of them reached statistical significance (Table 2)." Comment: Parameters were

Devices that emit this wavelength

Matched on wavelength within 15nm, since LED bins vary by roughly that much and a tighter match would be false precision. Where we have an irradiance figure, the session length is the time needed to reach this study's dose of 2 J/cm² at that intensity.

Matching a wavelength is not the same as reproducing a trial. Session times assume the device's published irradiance is accurate at the distance it was measured, which on brand-claim figures is often optimistic. Where a device publishes both a peak and an average we use the average, and where it publishes a falloff curve we use the lowest figure, so these times run long rather than short. Clinical protocols also control for spot size, contact and skin type in ways a home device cannot.